Abstract | INTRODUCTION: METHODS: A systematic search of English electronic databases was performed for studies with sufficient statistical power that were published between 2000 andl 30 August 2020, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses ( PRISMA) criteria. A total of 676 papers were screened, and 13 were found eligible to be included in the meta-analysis. Studies that included patients who suffered from MI or stroke and were under amlodipine treatment were included in the analysis. The odds ratio and the risk ratio of amlodipine compared to active control/placebo were noted from the studies and statistically analyzed. RESULTS:
Amlodipine had a significant effect in reducing stroke and MI in hypertensive patients. Similar to results published in reports, this systematic review proved that the hazard ratio for amlodipine was < 1 for stroke (0.69-1.04) and MI (0.77-0.98), showing that amlodipine accounted for better prevention of stroke and MI. CONCLUSION: In the pooled analysis of data from 12 randomised controlled trials and one double-blinded cohort study measuring the effect of CCBs, we found that the CCB amlodipine reduced the risk of stroke and MI in hypertensive patients. Superior results for amlodipine were found in ten of the 13 studies included in this meta-analysis.
|
Authors | Shamanna S Iyengar, Jagdish Chander Mohan, Saumitra Ray, M Srinivasa Rao, Mohammed Yunus Khan, Usha Rani H Patted, Kumar Gaurav |
Journal | Cardiology and therapy
(Cardiol Ther)
Vol. 10
Issue 2
Pg. 429-444
(Dec 2021)
ISSN: 2193-8261 [Print] England |
PMID | 34480745
(Publication Type: Journal Article, Review)
|
Copyright | © 2021. The Author(s). |